Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Simon Peter Gampenrieder; Markus Steiner; Clemens Hufnagl; H Hackl; Gabriel Rinnerthaler; T Westphal; Florian Huemer; C Monzo-Fuentes; Patrick Morre; Cornelia Hauser-Kronberger; Richard Greil

doi:10.1016/j.annonc.2022.03.057

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Simon Peter Gampenrieder, Markus Steiner, Clemens Hufnagl, H Hackl, Gabriel Rinnerthaler, T Westphal, Florian Huemer, C Monzo-Fuentes, Patrick Morre, Cornelia Hauser-Kronberger, Richard Greil

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	S141-S141
Journal	ANNALS OF ONCOLOGY
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.03.057
Publication status	Published - 2022

Access to Document

10.1016/j.annonc.2022.03.057

Cite this

Gampenrieder, S. P., Steiner, M., Hufnagl, C., Hackl, H., Rinnerthaler, G., Westphal, T., Huemer, F., Monzo-Fuentes, C., Morre, P., Hauser-Kronberger, C., & Greil, R. (2022). Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. ANNALS OF ONCOLOGY , 33, S141-S141. https://doi.org/10.1016/j.annonc.2022.03.057

Gampenrieder, Simon Peter ; Steiner, Markus ; Hufnagl, Clemens et al. / Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. In: ANNALS OF ONCOLOGY 2022 ; Vol. 33. pp. S141-S141.

@article{02cad62c0ae742a9afa999ef9cc6aa23,

title = "Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial",

author = "Gampenrieder, {Simon Peter} and Markus Steiner and Clemens Hufnagl and H Hackl and Gabriel Rinnerthaler and T Westphal and Florian Huemer and C Monzo-Fuentes and Patrick Morre and Cornelia Hauser-Kronberger and Richard Greil",

year = "2022",

doi = "10.1016/j.annonc.2022.03.057",

language = "English",

volume = "33",

pages = "S141--S141",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

}

Gampenrieder, SP , Steiner, M , Hufnagl, C, Hackl, H, Rinnerthaler, G, Westphal, T, Huemer, F, Monzo-Fuentes, C, Morre, P, Hauser-Kronberger, C & Greil, R 2022, 'Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial', ANNALS OF ONCOLOGY , vol. 33, pp. S141-S141. https://doi.org/10.1016/j.annonc.2022.03.057

Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. / Gampenrieder, Simon Peter ; Steiner, Markus ; Hufnagl, Clemens et al.
In: ANNALS OF ONCOLOGY , Vol. 33, 2022, p. S141-S141.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

AU - Gampenrieder, Simon Peter

AU - Steiner, Markus

AU - Hufnagl, Clemens

AU - Hackl, H

AU - Rinnerthaler, Gabriel

AU - Westphal, T

AU - Huemer, Florian

AU - Monzo-Fuentes, C

AU - Morre, Patrick

AU - Hauser-Kronberger, Cornelia

AU - Greil, Richard

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.03.057

DO - 10.1016/j.annonc.2022.03.057

M3 - Abstract (Journal)

SN - 0923-7534

VL - 33

SP - S141-S141

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

ER -

Gampenrieder SP , Steiner M , Hufnagl C, Hackl H, Rinnerthaler G, Westphal T et al. Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. ANNALS OF ONCOLOGY . 2022;33:S141-S141. doi: 10.1016/j.annonc.2022.03.057